Lymphangioma and Infantile Hemangioma — CPB 0817 | AETNA Coverage Update

Aetna modified CPB 0817 covering lymphangioma and infantile hemangioma treatment, effective December 4, 2025. Here's what billing teams need to know before submitting claims.

Aetna, a CVS Health company, updated its lymphangioma and infantile hemangioma coverage policy under CPB 0817 in the Aetna system. This policy governs a broad set of treatments — surgical excision (CPT 11400–11446), laser and cryosurgery destruction (CPT 17106–17111), intralesional injections (CPT 11900–11901), and radiation delivery (CPT 77401) — across pediatric and select adult patients. Sirolimus products (HCPCS J7520 and J9331) are explicitly excluded. If your practice treats infantile hemangiomas or performs sclerotherapy for lymphangioma, this update affects your medical necessity documentation and prior authorization strategy starting December 4, 2025.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Lymphangioma and Infantile Hemangioma
Policy Code	CPB 0817
Change Type	Modified
Effective Date	December 4, 2025
Impact Level	Medium-High
Specialties Affected	Pediatric surgery, dermatology, otolaryngology, interventional radiology, radiation oncology, vascular surgery
Key Action	Audit medical necessity documentation for all hemangioma and lymphangioma claims before submitting against this policy's updated criteria

---

Aetna Lymphangioma and Infantile Hemangioma Coverage Criteria and Medical Necessity Requirements 2025

The Aetna lymphangioma and infantile hemangioma coverage policy under CPB 0817 is a criteria-heavy policy. Coverage is not automatic — it requires documented clinical justification tied to specific indications. The real issue here is that "infantile hemangioma" billing is one of the most denial-prone areas in pediatric dermatology and surgery, because payers draw a sharp line between cosmetic and medically necessary treatment.

The Hemangioma Medical Necessity Threshold

Aetna covers treatment for hemangiomas of infancy when the lesion meets at least one of four criteria:

If none of those four conditions are present, the treatment will not meet medical necessity under this coverage policy. Document the specific criterion in your clinical notes. Vague language like "patient is distressed" does not clear the bar. "Ulcerated hemangioma with documented bleeding" does.

When medical necessity is established, the following treatments are covered — alone or in combination:

Oral Propranolol for Proliferating Infantile Hemangioma

Aetna covers oral propranolol for proliferating infantile hemangioma that requires systemic therapy — specifically, when corticosteroids are indicated. This is a meaningful coverage decision. Propranolol is now first-line treatment for many high-risk infantile hemangiomas, and Aetna's criteria align with standard clinical practice.

The inpatient initiation criteria are specific. Aetna considers inpatient admission medically necessary for propranolol initiation when at least one of the following applies:

#	Covered Indication Copy
1	The infant is eight weeks of age or younger (using corrected age, not chronological age — critical distinction for preterm infants)
2	The family lacks adequate social support
3	The infant has co-morbid conditions affecting the cardiovascular system, airway (including symptomatic respiratory hemangiomas), or blood glucose maintenance

The dosing protocol matters for reimbursement documentation. Propranolol starts at 0.33 mg/kg orally three times daily. Blood pressure and heart rate checks occur one and two hours after each administration. If three doses are tolerated, the dose increases to 0.66 mg/kg TID (2 mg/kg/day). Inpatient admission is medically necessary until the target dose is tolerated for two hours. Once that threshold is met, discharge is appropriate.

If you're billing inpatient stays for propranolol initiation outside these criteria, expect claim denial. The policy is explicit about what justifies the admission.

A note on corrected age: For preterm infants, Aetna uses corrected age — the infant's age calculated from the expected due date, not the birth date. An infant born four weeks early who is six weeks old by calendar is only two weeks by corrected age. That distinction determines whether inpatient initiation meets medical necessity. Make sure your clinical documentation uses corrected age for preterm patients.

Lymphangioma Coverage

Aetna covers sclerotherapy for lymphangioma treatment. The policy is straightforward here — no layered criteria like hemangioma. If your team is billing sclerotherapy for lymphangioma, this coverage policy supports it. Document the lymphangioma diagnosis (D18.1) and the treatment rationale.

Prior Authorization

The policy does not state a blanket prior authorization requirement, but CPB 0817 is a clinical criteria policy. Aetna uses these policies to support prior auth decisions and retrospective claim review. For inpatient propranolol initiation and for surgical excision or radiation therapy cases, confirm prior authorization requirements with the specific plan. Don't assume benefit-level prior auth rules override CPB 0817's medical necessity criteria — they work together.

---

Aetna Infantile Hemangioma Exclusions and Non-Covered Indications

Three treatment approaches for infantile hemangioma are explicitly experimental, investigational, or unproven under this policy. They will not receive reimbursement.

Atenolol for infantile hemangioma is not covered. This is notable. Some providers use atenolol as an alternative to propranolol, but Aetna has not accepted the evidence base. If your physicians are prescribing atenolol for this indication, prior authorization requests will be denied under CPB 0817.

Topical timolol is also excluded. This one surprises some teams — topical timolol has clinical momentum in the dermatology space for superficial hemangiomas, but Aetna has not moved it to covered status. Don't bill this expecting coverage.

Pigment epithelium-derived factor (PEDF) is excluded as well.

On the diagnostic side, Aetna will not cover measurements of endothelial and circulating C19MC microRNAs or serum vascular endothelial growth factor (VEGF) as biomarkers for infantile hemangioma.

Sirolimus for diffuse intestinal infantile hemangioma is also excluded. HCPCS codes J7520 (sirolimus oral, 1 mg) and J9331 (sirolimus protein-bound particles, 1 mg) are listed as not covered for these indications. If you're billing J7520 or J9331 against a hemangioma diagnosis, those claims will deny.

---

Coverage Indications at a Glance

---

Aetna Hemangioma and Lymphangioma Billing Guidelines and Action Items 2025

Copy Action Items

If you're managing a high volume of pediatric hemangioma cases, talk to your compliance officer before the effective date. The distinction between cosmetic and medically necessary treatment creates real claim denial risk, and the propranolol inpatient criteria are detailed enough that one documentation gap can reverse reimbursement on a costly admission.

---

CPT, HCPCS, and ICD-10 Codes for Lymphangioma and Infantile Hemangioma Under CPB 0817

Covered CPT Codes (When Selection Criteria Are Met)

Other CPT Codes Related to CPB 0817

Code	Type	Description	Notes Copy
77402	CPT	Radiation treatment delivery, ≥1 MeV; simple	Listed as related; verify individual plan coverage

Not Covered / Experimental HCPCS Codes

Code	Type	Description	Reason Copy
J7520	HCPCS	Sirolimus, oral, 1 mg	Not covered for hemangioma indications listed in CPB 0817
J9331	HCPCS	Injection, sirolimus protein-bound particles, 1 mg	Not covered for hemangioma indications listed in CPB 0817

Key ICD-10-CM Diagnosis Codes

---